There are proven successful approaches to clinical trial design in pulmonary arterial hypertension (PAH), which in turn have led to the licensing of a number of effective therapies. SSc has been included in trials of World Health Organization Group 1 PAH but has been under-represented. Responses in outcomes as diverse as exercise capacity, quality of life, durability of drug effect and survival have been reduced in comparison with those seen in idiopathic PAH. The PAH community has achieved international and interdisciplinary consensus guidelines for future studies. We consider the diverse outcome measures used in trials in the context of the complexities of scleroderma. An argument is advanced in favour of future trials focused exclusively on SSc but with adaptations of the core outcome measures and trial design templates applicable to more general studies of PAH.
Introduction and background
Pulmonary arterial hypertension (PAH) is only one aetiology for pulmonary hypertension per se. This Points to Consider article will focus on PAH, as PAH related to SSc (scleroderma) has been sufficiently studied to allow for regulatory approval and licensing. Successful templates for clinical trials are fully established [1] . However, the therapeutic response of SSc-PAH, in comparison with idiopathic PAH, is blunted in outcome domains of exercise capacity, quality of life, durability of drug effect and survival [2, 3] . We consider the need for specific adaptation of trial design to reflect issues that are unique to the SSc-PAH population.
Past trials of PAH therapies have typically been short term (1216 weeks) and have focused on exercise capacity and quality of life. More robust data on survival, occurrence of major clinical events and durability of therapeutic response have been derived from open-label follow-up cohorts or from disease-specific registries. Longer-term trials that permit measurement of worsening events are recent developments [1, 46] . Head-to-head comparisons of therapies are lacking.
In recent years, a multidisciplinary international panel of experts (Expert Panel on Outcomes in Systemic Sclerosis) has published the results of structured reviews of the literature regarding outcome measures used in PAH clinical trials. Based on the criteria of the OMERACT filter, no outcome measure other than right heart catheterization [3] can be considered fully validated [7, 8] (Table 1) .
Specific measures of outcome
Six-minute walk distance
The 6-min walk distance (6MWD) has served as the primary measure of efficacy in all randomized controlled trials of treatments for PAH since the first such trial with epoprostenol [9] . The measure is typically presented as a placebo-corrected variable. Recent studies have attempted to address the issue of minimally important difference, that is, how much improvement is necessary to be perceived as beneficial [10] , now considered as 38.642.8 m on treatment.
Results in many trials in SSc-PAH have failed to achieve this magnitude of effect, probably because there are confounding issues with use of the 6MWD in patients with SSc. Fatigue, deconditioning, impaired skeletal muscle perfusion, lower extremity ulcerations, concomitant interstitial lung disease and mechanical difficulties with ambulation are all confounding disease features [1114] . For this reason, many believe that 6MWD should not be used as a primary outcome in SSc-PAH trials. Despite these data, arguments support the use of 6MWD as a categorical threshold variable wherein achieving or maintaining a distance of greater than $380 m is associated with improved survival [15, 16] . In SSc-PAH, cardiac output is independently correlated with 6 MW at baseline, but accounts for a small amount of the variance of 6MWD, suggesting that other non-haemodynamic factors could have an impact on 6MWD. Moreover, variations of 6MWD do not reflect changes in haemodynamics among treated patients, indicating that 6MWD is not an accurate surrogate marker for haemodynamic severity, nor an appropriate outcome measure to assess changes in haemodynamics during follow-up in treated SSc-PAH [16].
Functional class
World Health Organization (WHO) functional class has been used as the primary measure of functional impairment in PAH trials. Adapted from the New York Heart Association (NYHA) criteria for heart failure, improvements in functional class have gained status in drug labelling and provide a framework for selection of therapy based on clinical severity [1, 17] . As with many global rating scales, there is strong evidence of high levels of both inter-and intra-observer inconsistency [18] .
Biomarkers
Brain natriuretic peptide is a sensitive marker of ventricular myocyte strain. Brain natriuretic peptide has demonstrated utility as a non-invasive screening test for detection of PAH [19, 20] , and data are becoming available that attest to its value in the serial assessment of response to therapy in SSc-PAH [21] .
Echocardiography
Echocardiography with Doppler is a key element in noninvasive screening programmes for early detection of PAH [22, 23] . Serial assessment focuses on the size and functional status of the right ventricle [1, 17, 24, 25] .
Haemodynamics
Serial measurement by right heart catheterization of pulmonary artery pressure, cardiac output and pulmonary vascular resistance is core to demonstrating proof of concept when testing new agents. As a study outcome, 
Specific recommendations for consideration for trial design of SSc-PAH

Primary outcome measures
The 6MWD test remains the most frequently used primary measure of outcome in SSc-PAH, despite its lack of responsiveness in this disease. Although issues remain with regard to its full validation, it is feasible with strong face validity and has performed reasonably well in previous trials of PAH. Unfortunately, it is frequently not responsive in the 2025% of SSc patients in these trials (4, 1114, 16). Non-parametric comparison of treatment effect remains the preferred approach to analysis if the 6MWD is being considered, although categorical responses, including improvement to above a pre-designated threshold value, improvement to a pre-defined level of clinical meaningfulness and/or prevention of deterioration, are potential secondary analyses.
Secondary outcome measures
Measures of patient functional capacity and quality of life are crucial to successful drug approval and development of instructive package labelling and should be strongly considered. These can include physician-rated instruments, such as assignation of WHO/NYHA functional class or patient-reported outcomes, including dyspnoea questionnaires, generic measures of quality of life such as the Short Form-36 and patient global assessments.
Event-driven trial design
Analysis of the frequency of pre-defined clinical events reflecting mortality and morbidity or the time to occurrence of events is a robust approach to drug study. Although such trials include the traditional measures of outcome, they focus on measures of major changes in clinical status (survival, hospitalization, need for additional therapy, meaningful decreases in 6MWD) and require a larger study population, a longer period of observation and use of a blinded adjudication committee. At least three studies testing macitentan, selexipag and the initial combination of ambrisentan and tadalafil have been successfully carried out according to this construct [46] , but these trials required >500 subjects followed for a median treatment duration of > 2 years. These measures, although not fully validated, need to be considered strongly with a potential for validating their use during the course of a predefined clinical trial.
Study design and duration
Studies of agents with primary effects as vasodilators have typically required at least 812 weeks on full dosage to demonstrate significant effects on exercise capacity and quality of life. Studies of agents with the potential to foster vascular deremodelling have been as short as 12 weeks as well. Studies based on event-driven trial design require a duration of at least 12 months with a large sample size or even longer duration in smaller populations.
At the present time, placebo-controlled parallel treatment design remains the approach of choice [28] . Even shortterm trials have demonstrated important declines in exercise capacity, quality of life and mortality/morbidity events in patients randomized to placebo. Some studies suggest that patients initially randomized to placebo do not catch up with those on active treatment during open-label followup [29] . The availability of multiple proven effective agents has challenged the ethical construct of further use of placebo in treatment-naïve patients [1] . A priori stratification of trial enrollees between those who are treatment naïve and those who are stable on established therapy has been used, although treatment effect appears to be blunted in the latter group [30] . The future may demonstrate increasing use of non-inferiority trial designs, although these typically require a larger study sample size [1] .
Inclusion criteria
Subjects should have established SSc according to EULAR/ACR criteria [31] , and in all instances it is required that the diagnosis of PAH be firmly established by right heart catheterization [18] .
Exclusion criteria
Great care should be taken to assess and perhaps exclude subjects with confounding co-morbidities (pulmonary veno-occlusive disorder, parenchymal lung disease such as clinically relevant interstitial lung disease, left heart dysfunction) [18, 32] and to exclude patients with other connective tissue disorders, such as SLE.
Synthesis
With appropriate adaptation, the outcome measures applicable to PAH can and are applied to studies of SSc-PAH. As 6MWD is poorly responsive in SSc-PAH, eventdriven trial designs can be considered, although validation of these measures remains a concern. One benefit of study of SSc-PAH in isolation would be the ability to measure other disease-specific secondary outcomes, including RP, digital ulcers, ventilationperfusion effects and effects on gastrointestinal and left ventricular function.
Conclusion
Patients with SSc have difficulties with the 6MWD, a prime measure in trials for PAH therapy. Serial haemodynamic measures by right heart catheterization are core to demonstrating proof of concept when testing new agents in SSc. Future trials focused exclusively on SSc are needed but with adaptations of the core outcome measures and trial design templates applicable to SSc.
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